Panelists discuss how the progression of type 1 diabetes unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.
Panelists discuss how adhering to screening guidelines for type 1 diabetes enables early detection and intervention, improving patient outcomes and delaying disease progression through timely treatments like teplizumab.
Panelists discuss how managing the clinical, financial, and quality-of-life burdens of type 1 diabetes (T1D) requires early intervention, proactive care strategies, and the use of treatments like teplizumab to improve patient outcomes and reduce long-term complications.
Panelists discuss how antibody screening for type 1 diabetes can identify at-risk individuals early, enabling proactive monitoring and intervention to delay or prevent disease onset.
Panelists discuss how teplizumab therapy can delay the onset and progression of type 1 diabetes (T1D) by preserving β-cell function and reducing the risk of developing full-blown diabetes in at-risk individuals.
Panelists discuss clinical use of teplizumab including patient selection, navigating approval processes, and managing the 14-day infusion regimen to optimize outcomes and delay the progression of type 1 diabetes.
Panelists discuss how delaying intervention between stage II and stage III T1D can result in irreversible β-cell loss, higher rates of complications, and poorer overall outcomes for patients.
Panelists discuss how understanding the stages of type 1 diabetes (T1D) progression is crucial for early intervention, with a focus on delaying disease advancement through proactive treatments like teplizumab.
Panelists discuss how delaying intervention in stage 2 T1D can lead to faster disease progression, increased risk of complications like diabetic ketoacidosis, and greater long-term burden on patient health and quality of life.
Panelists highlight the burden of type 1 diabetes including the significant physical, emotional, and financial challenges faced by patients and their families, emphasizing the need for early intervention and proactive management strategies.
The expert panel concludes by analyzing a patient case and offering final insights on customizing treatment for complex geriatric diabetes patients, taking into account cardiovascular health, weight management, and renal function considerations.
Key opinion leaders explore methods for optimizing treatment in older adults with type 2 diabetes, focusing on streamlining regimens and the process of deprescribing, with particular emphasis on defining and implementing the deprescribing approach.
Experts examine strategies for managing treatment modifications in older adults with type 2 diabetes, weighing the approaches, challenges, and advantages of combination therapy regimens.
Leading experts in geriatric diabetes care explore comprehensive aspects of insulin therapy, including dosing strategies, available injectable options, and methods for tailoring glucose control in elderly patients.
The panelists analyze a patient case, examining treatment profiles, adherence factors, and drug class selection criteria while discussing strategies to enhance elderly care.
Key opinion leaders explore strategies for enhancing elderly patient care by implementing American Diabetes Association guidelines on glycemic targets and long-term management in geriatric settings.
Key opinion leaders in the management of diabetes delineate the definition of older patients and examine the implications of homeostenosis, a condition that disrupts homeostatic mechanisms in aging individuals.
Medha Munshi, MD, and Javier Morales, MD, FACP, FACE, emphasize the significance of personalized diabetes management, emphasizing age and other patient-specific factors as crucial considerations for optimizing care.
